P579: Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s diseaseECCO'22Year: 2022
Authors: Derikx, L.(1,2);Plevris, N.(2);Su, S.(2);Gros, B.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cook, N.(3,4);Jenkinson, P.(2);O'Hare, C.(2);Merchant, L.(2);Noble, C.(2);Arnott, I.(2);Jones, G.(2,5);Lees, C.(2,4);
(1)Radboud University Nijmegen Medical Centre, Inflammatory Bowel Disease Centre- Department of Gastroenterology and Hepatology- Route 455, Nijmegen, The Netherlands;(2)Western General Hospital, Edinburgh IBD Unit, Edinburgh, United Kingdom;(3)University of Edinburgh, MRC Human Genetics Unit- Institute of Genetics and Molecular Medicine-, Edinburgh, United Kingdom;(4)University of Edinburgh, Centre for Genomics and Experimental Medicine- Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom;(5)University of Edinburgh, Centre for Inflammation Research- The Queen's Medical Research Institute, Edinburgh, United Kingdom;
P580: Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort studyECCO'22Year: 2022
Authors: de Voogd, F.(1);Bots, S.(1);Gecse, K.(1);Gilja, O.H.(2);D'Haens, G.(1);Nylund, K.(2);
(1)Amsterdam University Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Haukeland University Hospital, National Centre for Ultrasound in Gastroenterology, Bergen, Norway;
P581: Transmural remission improves clinical outcomes up to 5 years in patients with Crohn’s DiseaseECCO'22Year: 2022
Authors: Pedro, J.(1);Botto, I.(1);Fernandes, S.(1);Lemos, J.(2);Neves, J.(3);Campelo, P.(3);Carvalho, D.(4);Bernardo, S.(1);Gonçalves, A.R.(1);Valente, A.(1);Moura Santos, P.(1);Rosa, I.(2);Tavares de Sousa, H.(3);Ramos, J.(4);Venâncio, J.(5);Leitão, J.(6);Claro, I.(2);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Universitário Lisboa Norte, Serviço de Gastrenterologia e Hepatologia, Lisboa, Portugal;(2)Instituto Português de Oncologia de Lisboa Francisco Gentil, Serviço de Gastrenterologia, Lisboa, Portugal;(3)Centro Hospitalar Universitário do Algarve- Algarve Biomedical Center, Serviço de Gastrenterologia, Faro, Portugal;(4)Hospital Santo António dos Capuchos – Centro Hospitalar Universitário Lisboa Central, Serviço de Gastrenterologia, Lisboa, Portugal;(5)Instituto Português de Oncologia de Lisboa Francisco Gentil, Serviço de Radiologia, Lisboa, Portugal;(6)Centro Hospitalar Universitário Lisboa Norte, Serviço de Radiologia, Lisboa, Portugal;
P582: Association between serum ustekinumab concentrations and endoscopic disease activity in Crohn’s diseaseECCO'22Year: 2022
Authors: Yanofsky, R.(1);Abduallah, Y.(1);Golovics, P.(2);Lakatos, P.L.(2);Bitton, A.(2);Wild, G.(2);Afif, W.(2);Bessissow, T.(2);
(1)McGill University, Internal Medicine, Montreal, Canada;(2)McGill University, Gastroenterology, Montreal, Canada;
P583: Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicenter cohort studyECCO'22Year: 2022
Authors: Avni Biron, I.(1);Mishael, T.(2);Zittan, E.(3);Livne, M.(4);Zinger, A.(5);Tzadok, R.(6); Goldenberg, R.(7);kopylov, U.(4);Ron, Y.(6);Hadar, E.(8);Helman, S.(2);Ollech, J.(1);Farkash, R.(7);Pauker, M.(1);Yanai, H.(1);Dotan, I.(1);Bar-Gil Shitrit , A.(7);
(1)Rabin Medical Center - Beilinson Hospital, Division of Gastroenterology, Petah Tikva, Israel;(2)Shaare Zedek Medical Center, Obstetrics and Gynecology Division, Jerusalem, Israel;(3)Emek Medical Center, Ellen and Pinchas Mamber Institute of Gastroenterology and Liver Diseases, Afula, Israel;(4)Sheba Medical Center, Institute of Gastroenterology, Tel Hashomer, Israel;(5)Hadassah Medical Center, Department of Gastroenterology, Jerusalem, Israel;(6)Tel Aviv medical center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(7)Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel;(8)Rabin Medical Center - Beilinson Hospital, Maternal fetal medicine- Helen Schneider hospital of women, Petah Tikva, Israel;
P585: Examining faecal incontinence and its impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a multi-country burden of illness studyECCO'22Year: 2022
Authors: Karki, C.(1);Athavale, A.(2);Hantsbarger, G.(3);Lee, K.(4);Milicevic, S.(5);Perovic, M.(6);Raven, L.(7);Sajak-Szczerba, M.(8);Sharpe, E.(9);Tozer, P.(10);
(1)Takeda Pharmaceuticals USA Inc., Global Evidence and Outcomes, Cambridge- MA, United States;(2)Trinity Partners- LLC., Insights & Analytics, Waltham- MA, United States;(3)Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States;(4)Crohn's and Colitis Canada, Research & Patient Programs, Toronto, Canada;(5)Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland;(6)European Federation of Crohn’s and Ulcerative Colitis Associations, European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium;(7)Crohn's and Colitis Australia, n/a, Camberwell, Australia;(8)European Federation of Crohn’s and Ulcerative Colitis Associations, n/a, Brussels, Belgium;(9)Trinity Partners- LLC, Heath Economics & Outcomes Research, Waltham- MA, United States;(10)St Mark’s Hospital and Academic Institute, Fistula Research unit, London, United Kingdom;
P586: Surgical recurrence in Crohn’s Disease: Can we prevent it?ECCO'22Year: 2022
Authors: Botto, I.(1);Serrazina, J.(1);Coelho Rodrigues, I.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Universitário Lisboa Norte, Serviço de Gastrenterologia, Lisbon, Portugal;
P587: Disease severity in the INFLAMMATORY BOWEL DISEASES: Do patients and physicians agree?ECCO'22Year: 2022
Authors: Timmer, A.(1);de Sordi, D.(1);Neuser, J.(1);Seibel, K.(1);Hensel, A.(1);Schmidt-Lauber, M.(2);Allgayer, H.(3);Klebl, F.(4);Obermeier, F.(4);Jessen, P.(5);Schnoy, E.(6);Helwig, U.(7);Morgenstern, J.(8);Leifeld, L.(9);Schmidt, S.(9);Meinhardt, C.(10);Maaser, C.(11);Bästlein, E.(12);Bokemeyer, A.(13);Graefe, U.(14);Kühbacher, T.(15);Kaltz, B.(16);Sander, C.(16);Wolfgang, K.(17);
(1)Carl von Ossietzky University Oldenburg, Epidemiology and Biometry, Oldenburg, Germany;(2)Gastroenterologische Praxis, Gastroenterology, Oldenburg, Germany;(3)Reha-Kliniken, Gastroenterologie, Bad Brückenau, Germany;(4)Praxiszentrum, Gastroenterology, Regensburg, Germany;(5)Gemeinschaftspraxis, Gastroenterology, Altenholz, Germany;(6)Uniklinikum Augsburg, Med Klinik III, Augsburg, Germany;(7)Internistische Praxengemeinschaft, Gastroenterology, Oldenburg, Germany;(8)Evangelisches Krankenhaus Kalk, Gastroenterology, Köln, Germany;(9)St. Bernward Krankenhaus, Innere und Gastroenterologie, Hildesheim, Germany;(10)Klinikum Oldenburg, Gastroenterology, Oldenburg, Germany;(11)Klinikum Lüneburg, Gastroenterology, Lüneburg, Germany;(12)Magen-Darm-Zentrum Köln, Gastroenterology, Köln, Germany;(13)Uniklinikum Essen, Gastroenterology, Essen, Germany;(14)Gastropraxis, Gastroenterology, Berlin, Germany;(15)Medius-Kliniken, Gastroenterology, Nürtingen, Germany;(16)DCCV, e.V., Berlin, Germany;(17)Uniklinikum, Gastroenterology, Köln, Germany;
P588: T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatmentECCO'22Year: 2022
Authors: Mayorga Ayala, L.F.(1);Herrera-deGuise, C.(1);Esperalba, J.(2);Martinez-Gomez, X.(6);Céspedes Martinez, E.(1);Robles Alonso, V.(1);Jimenez, A.(1);Perez Martinez, Z.(1);Oller, E.(1);Ibarz, A.(1);Fernandez-Naval, C.(3);Martinez-Gallo, M.(4);Lopez Messeguer, M.(5);Casellas, F.(1);Borruel, N.(1);
(1)Unitat d’Atenció Crohn-Colitis, Servei d'Aparell Digestiu- Hospital Universitari Vall d'Hebron- Barcelona- Catalonia- Spain, Barcelona, Spain;(2)Universitat Autónoma de BarcelonaUAB- Barcelona- Catalonia- Spain, Servei de Microbiologia- Hospital Universitari Vall d'Hebron- Barcelona- Catalonia- Spain, Barcelona, Spain;(3)Universitat Autónoma de BarcelonaUAB- Barcelona- Catalonia- Spain, Servei de Microbiologia- Hospital Universitari Vall d'Hebron, Barcelona, Spain;(4)Universitat Autónoma de Barcelona UAB- Barcelona- Catalonia- Spain., Servei d'Immunologia- Hospital Universitari Vall d'Hebron- Barcelona- Catalonia- Spain, Barcelona, Spain;(5)Servei de Pneumologia, Hospital Universitari Vall d´Hebron- Barcelona, Barcelona, Spain;(6)Universitat Autónoma de BarcelonaUAB- Barcelona- Catalonia- Spain, Servei de Epidemiologia- Hospital Universitari Vall d'Hebron, Barcelona, Spain;
P589: Total thiopurine exposure and impact on the development of keratinocyte carcinomas in Inflammatory Bowel Disease patients; a case control studyECCO'22Year: 2022
Authors: Jansen, F.M.(1);Lubeek, S.(2);den Broeder, N.(3);Savelkoul, E.(1);Marcus, C.(1);Hoentjen, F.(1,4);van Dop, W.(1);
(1)Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Radboud University Medical Center, Department of Dermatology, Nijmegen, The Netherlands;(3)Radboud University Medical Center, Department of Rheumatology, Nijmegen, The Netherlands;(4)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;In cooperation with ‘PALGA’ (a nationwide network and registry of histo- and cytopathology in the Netherlands)
P590: Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panelECCO'22Year: 2022
Authors: Hansen, R.(1);Meade, S.(2);Torrente, F.(3);Kammermeier, J.(4);Croft, N.M.(5);de Ridder, L.(6);Wilson, D.C.(7);Klomberg, R.(6);Turner, D.(8);Martín-de-Carpi, J.(9);Bronsky, J.(10);Benchimol, E.(11);Amil-Dias, J.(12);Mack, D.R.(13);Walker, G.(14);Powar, M.(15);Burgess, N.(16);van Ommen, C.H.(17);Irving, P.M.(18);Samaan, M.(18);
(1)Royal Hospital for Children- Glasgow, Department of Paediatric Gastroenterology, Glasgow, United Kingdom;(2)King's College NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(3)Cambridge University Hospitals NHS Foundation Trust, Department of Paediatric Gastroenterology, Cambridge, United Kingdom;(4)Evelina London Children’s Hospital, Department of Paediatric Gastroenterology, London, United Kingdom;(5)Queen Mary University of London, Centre for Immunobiology- Blizard Institute, London, United Kingdom;(6)Sophia Children's Hospital Erasmus MC, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(7)University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom;(8)Shaare Zedek Medical Centre- The Hebrew University of Jerusalem-, Department of Paediatric Gastroenterology, Jerusalem, Israel;(9)Hospital Sant Joan de Déu, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Barcelona, Spain;(10)University Hospital Motol, Department of Paediatrics, Prague, Czech Republic;(11)The Hospital for Sick Children- University of Toronto, Division of Gastroenterology- Hepatology and Nutrition- Department of Paediatrics, Toronto, Canada;(12)Hospital Lusíadas, Department of Pediatric Gastroenterology, Porto, Portugal;(13)Children’s Hospital of Eastern Ontario and University of Ottawa, Department of Pediatrics, Ottawa, Canada;(14)Royal Hospital for Children- Glasgow, Department of Paediatric Surgery, Glasgow, United Kingdom;(15)Cambridge University Hospitals NHS Foundation Trust, Cambridge Colorectal Unit, Cambridge, United Kingdom;(16)The Royal London Hospital, Department of Paediatric Gastroenterology, London, United Kingdom;(17)Sophia Children's Hospital Erasmus MC, Department of Paediatric Hematology-Oncology, Rotterdam, The Netherlands;(18)Guy's and Saint Thomas' NHS Foundation Trust, IBD Unit, London, United Kingdom;
P591: Biological therapies and small molecules show to be efficacious in patients with moderate-to-severe ulcerative proctitis.ECCO'22Year: 2022
Authors: Lemmens, P.(1);Guedelha Sabino, J.(1,2);Dubois, E.(1);Verstockt, B.(1,2);Vermeire, S.(1,2);Ferrante, M.(1,2);
(1)UZ Leuven, Departement of Gastro-enterology and Hepatology, Leuven, Belgium;(2)KU Leuven, Translational Research Centre for Gastrointestinal Disorders TARGID, Leuven, Belgium;
P592: Effectiveness and safety of thioguanine in thiopurine-naïve Inflammatory Bowel Disease patientsECCO'22Year: 2022
Authors: Crouwel, F.(1);Bayoumy, A.B.(1);Mulder, C.J.J.(1);Peters, J.H.C.(2);Boekema, P.J.(3);Derijks, L.J.J.(4);De Boer, S.Y.(5);van de Meeberg, P.C.(5);Ahmad, I.(6);Buiter, H.J.C.(7);de Boer, N.K.(1);
(1)Amsterdam UMC- location VUmc, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Rode Kruisziekenhuis, Department of Gastroenterology and Hepatology, Beverwijk, The Netherlands;(3)Maxima Medical Centre, Department of Gastroenterology and Hepatology, Veldhoven, The Netherlands;(4)Maxima Medical Centre, Department of Clinical Pharmacy and Pharmacology, Veldhoven, The Netherlands;(5)Slingeland Hospital, Department of Gastroenterology and Hepatology, Doetinchem, The Netherlands;(6)Streekziekenhuis Koningin Beatrix, Department of Gastroenterology and Hepatology, Winterswijk, The Netherlands;(7)Amsterdam UMC- location VUmc, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands;
P594: Vedolizumab dose intensification does not always improve treatment persistence.ECCO'22Year: 2022
Authors: Hilley, P.(1);Peterson, A.R.(1);Wong , D.(1,2);Hine, K.(1);Srinivasan, A.(1);Choy, M.C.(1,2);De Cruz, P.(1,2);
(1)Austin Health, Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine- Austin Academic Centre, Melbourne, Australia;
P595: Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patientsECCO'22Year: 2022
Authors: Van Moorsel, F.(1,2);Deben, D.(3);Creemers, R.(4,5);Winkens, B.(6);Pierik, M.(7);Bus, P.(8);Simsek, M.(9);de Boer, N.(9);van Bodegraven, A.(4);Wong, D.(3);
(1)Jeroen Bosch Hospital, Department of Pharmacy, s-Hertogenbosch, The Netherlands;(2)Bernhoven Hospital, Dept. of Clinical Pharmacy, Uden, The Netherlands;(3)Zuyderland Medical Centre, Dept. of Clinical Pharmacy- Clinical pharmacology and Toxicology, Sittard-Geleen/Heerlen, The Netherlands;(4)Zuyderland Medical Centre, Dept. of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen/Heerlen, The Netherlands;(5)Maastricht University Medical Centre, 5Dev. of Gastroenterology and Hepatology, Maastricht, The Netherlands;(6)Maastricht University Medical Centre, Dept. of methodology and statistics, Maastricht, The Netherlands;(7)Maastricht University Medical Centre, Dev. of Gastroenterology and Hepatology, Maastricht, The Netherlands;(8)Laurentius Hospital, Dept. of Gastroenterology and Hepatology, Roermond, The Netherlands;(9)Amsterdam University Medical Centre, Dept. of Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P596: Adalimumab use in Paediatric Inflammatory Bowel Disease: A single centre real-life experienceECCO'22Year: 2022
Authors: El-Lababidi, N.(1,2);Frühauf, P.(2,2);
(1)General University Hospital in Prague- Czech Republic, Department of Paediatrics and Inherited Metabolic Disorders, Prague, Czech Republic;(2)First Faculty of Medicine- Charles University in Prague- Czech Republic, Department of Paediatrics and Inherited Metabolic Disorders, Prague, Czech Republic;
P597: Bone mineral density in patients after total proctocolectomy and pouch surgery due to Ulcerative Colitis have low bone mineral density, and low performance of DXA scans- a cross sectional studyECCO'22Year: 2022
Authors: Pfeffer-Gik, T.(1,2);Godny, L.(1,2);Ollech , J.(1,2);Wasserberg, N.(2,3);Barkan , R.(1);White, I.(2,3);Yackobovitch Gavan, M.(4,5);Kraizler, M.(1);Yanai , H.(1,2);Dotan, I.(1,2);
(1)Rabin Medical center, Division of Gastroenterology, Petah Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Rabin Medical center, Division of Surgery Colorectal Unit, Petah Tikva, Israel;(4)Schneider Children's Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes- National Center for Childhood Diabetes, Petah Tikva, Israel;(5)Tel Aviv University, Dept. of Epidemiology and Preventive Medicine- School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;
P598: Indicators for inadequate response among patients with Ulcerative Colitis treated with advanced therapies in German clinical practiceECCO'22Year: 2022
Authors: Bokemeyer, B.(1);Picker, N.(2);Kromer, D.(2);Rosin, L.(3);Patel, H.(4);
(1)Gastroenterology Practice, Minden, Minden, Germany;(2)Ingress Health HWM, GmbH, Wismar, Germany;(3)Galapagos Biopharma Deutschland, GmbH, München, Germany;(4)Galapagos, Nv, Mechelen, Belgium;
